Brierley J, Peters MJ Distinct hemodynamic patterns of septic shock at presentation to pediatric intensive care. Pediatrics. 2008 Oct;122(4):752-9. doi: 10.1542/peds.2007-1979.
Chand R, Mehta Y, Trehan N Cardiac output estimation with a new Doppler device after off-pump coronary artery bypass surgery. J Cardiothorac Vasc Anesth. 2006 Jun;20(3):315-9. Epub 2006 Jan 18.
Chen L, Kim Y, Santucci KA Use of ultrasound measurement of the inferior vena cava diameter as an objective tool in the assessment of children with clinical dehydration. Acad Emerg Med. 2007 Oct;14(10):841-5.
Critchley LA, Peng ZY, Fok BS, Lee A, Phillips RA Testing the reliability of a new ultrasonic cardiac output monitor, the USCOM, by using aortic flowprobes in anesthetized dogs. Anesth Analg. 2005 Mar;100(3):748-53, table of contents.
Deep A, Goonasekera CD, Wang Y, Brierley J Evolution of haemodynamics and outcome of fluid-refractory septic shock in children. Intensive Care Med. 2013 Sep;39(9):1602-9. doi: 10.1007/s00134-013-3003-z. Epub 2013 Jun 28.
Hershkovitz R, Sheiner E, Mazor M Ultrasound in obstetrics: a review of safety. Eur J Obstet Gynecol Reprod Biol. 2002 Feb 10;101(1):15-8. Review.
Jain S, Allins A, Salim A, Vafa A, Wilson MT, Margulies DR Noninvasive Doppler ultrasonography for assessing cardiac function: can it replace the Swan-Ganz catheter? Am J Surg. 2008 Dec;196(6):961-7; discussion 967-8. doi: 10.1016/j.amjsurg.2008.07.039.
Kern JW, Shoemaker WC Meta-analysis of hemodynamic optimization in high-risk patients. Crit Care Med. 2002 Aug;30(8):1686-92. Review.
Kosiak W, Swieton D, Piskunowicz M Sonographic inferior vena cava/aorta diameter index, a new approach to the body fluid status assessment in children and young adults in emergency ultrasound--preliminary study. Am J Emerg Med. 2008 Mar;26(3):320-5. doi: 10.1016/j.ajem.2007.07.012.
Odetola FO, Gebremariam A, Freed GL Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics. 2007 Mar;119(3):487-94.
Patel N, Dodsworth M, Mills JF Cardiac output measurement in newborn infants using the ultrasonic cardiac output monitor: an assessment of agreement with conventional echocardiography, repeatability and new user experience. Arch Dis Child Fetal Neonatal Ed. 2011 May;96(3):F206-11. doi: 10.1136/adc.2009.170704. Epub 2010 Jul 6.
Phillips RA, Paradisis M, Evans NJ, et al (2006) Validation of USCOM CO measurements in preterm neonates by comparison with echocardiography. Crit Care Med 10(S1): 144-343
Schratz LM, Meyer RA, Schwartz DC Serial intracoronary ultrasound in children: feasibility, reproducibility, limitations, and safety. J Am Soc Echocardiogr. 2002 Aug;15(8):782-90.
Su BC, Yu HP, Yang MW, Lin CC, Kao MC, Chang CH, Lee WC Reliability of a new ultrasonic cardiac output monitor in recipients of living donor liver transplantation. Liver Transpl. 2008 Jul;14(7):1029-37. doi: 10.1002/lt.21461.
Tan HL, Pinder M, Parsons R, Roberts B, van Heerden PV Clinical evaluation of USCOM ultrasonic cardiac output monitor in cardiac surgical patients in intensive care unit. Br J Anaesth. 2005 Mar;94(3):287-91. Epub 2005 Jan 14.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.